Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection

Article Abstract:

Women may have a different response to the AIDS virus as well as a different response to AIDS drugs. In a study of 438 HIV-infected women and 2,029 HIV-infected men, women had lower blood levels of virus and often had to reduce their dose of AIDS drugs. They were also less likely to progress to AIDS than the men.

Author: Hammer, Scott M., Katzenstein, David A., Currier, Judith S., Spino, Cathie, Grimes, Janet, Wofsy, Constance B., Hughes, Michael D., Cotton, Deborah J.
Research, Women, Sex factors in disease, Disease sex factors, HIV infection in women

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter

Article Abstract:

Combining zidovudine with didanosine or zalcitabine appears to prolong survival. Researchers randomly assigned 2,467 HIV-infected patients with CD4 counts between 200 and 500 to take zidovudine alone, zidovudine and didanosine, zidovudine and zalcitabine, or didanosine alone. Fewer patients who received combination therapy experienced a 50% drop in their CD4 counts, developed an AIDS-related illness or died. Even didanosine alone appeared to be more effective than zidovudine alone. Combination therapy is becoming the standard in the treatment of HIV infection.

Author: Hirsch, Martin S., Hammer, Scott M., Katzenstein, David A., Schooley, Robert T., Lederman, Michael M., Hughes, Michael D., Phair, John P., Merigan, Thomas C., Gundacker, Holly, Niu, Manette, Haubrich, Richard H., Henry, W. Keith
Drug therapy

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter

Article Abstract:

A decline in the level of HIV RNA in the blood of HIV-infected patients can signify a slower progression of the disease. This was demonstrated in the AIDS Clinical Trials Group (ACTG) Study 175, which randomly assigned 391 HIV-infected patients with CD4 counts between 200 and 500 to zidovudine alone, zidovudine and didanosine, zidovudine and zalcitabine or didanosine alone. Combination drug therapy resulted in a significantly greater decline in HIV RNA levels. Higher baseline RNA levels, a smaller drop in RNA levels and the presence of syncytium-forming virus were all associated with a greater risk of disease progression.

Author: Hirsch, Martin S., Hammer, Scott M., Katzenstein, David A., Fiscus, Susan, Hughes, Michael D., Jackson, J. Brooks, Merigan, Thomas C., Rasheed, Suraiya, Gundacker, Holly, Elbeik, Tarek, Reichman, Richard, Japour, Anthony
Measurement, Physiological aspects, RNA

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: HIV infections, Evaluation, HIV infection, Zidovudine, Drug therapy, Combination, Combination drug therapy, Didanosine, Zalcitabine
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.